Navigation Links
Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
Date:7/31/2008

26.2 1,227.0

_________ _________

Total liabilities and shareholders' equity 4,202.8 4,330.1

_________ _________

Unaudited US GAAP results for the three and six months to June

30, 2008 Consolidated Statements of Operations

3 months 3 months 6 months 6 months

to June to June to June to June

30, 30, 30, 30,

2008 2007(1) 2008 2007(1)

$M $M $M $M

________ ________ ________ ________

Revenues:

Product sales 705.7 504.2 1,337.4 965.7

Royalties 64.8 64.0 129.9 123.5

Other revenues 5.1 6.7 10.5 13.9

________ _______ ________ ________

Total revenues 775.6 574.9 1,477.8 1,103.1

________ _______ ________ ________

Costs and expenses:

Cost of product sales(1) (2) (3) 142.9 74.0 233.2 141.3

Research and development(1) (3) 145.3 103.1 267.3 184.2

Selling, general and

administrative(1) (2) 428.8 280.6 763.3 519.2

Integration costs - 1.3 - 1.3

Gain on sale of product rights (9.1) (5.0) (16.7) (5.0)

In-process R&D charge 135.0 1,896.0 135.0 1,896.0

________ _______ ________ ________

Total operating expenses 842.9
'/>"/>

SOURCE Shire Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)... BioSpecifics Technologie...any developing first-in-class collagenase-based pr...the third quarter ended September 30, 2009. ,,...is year, the FDA,s Arthritis Advisory Committee un...oval of XIAFLEX(TM) for the treatment of Dupuytren...
(Date:11/5/2009)... WaferGen Biosystems, In... of state-of-the-art genetic analysis systems, tod...ned the company,s Scientific Advisory Board. His ...lizing novel molecular diagnostics for cancer dete...nt of computational biology systems for several bi...
(Date:11/5/2009)...IK Surgery and vision correction experts listed in...y involved at the recently concluded American Acad...San Francisco, California. Dr. Stephen Brint, MD, ...rf, MD, Dr. Peter Rapoza, MD, Dr. Michael Raizman,...MD, Dr. Edward Manche, MD, and Dr. Parag Majmudar,...
(Date:11/4/2009)...4 DIATHERIX Laboratories, Inc. (DI...at the Michigan Security Network Homeland Security...ennis Grimaud, Chairman and Chief Executive Office...y,s advanced molecular diagnostic testing on bio-p... diagnosis and military efforts. ,, "This conf...
Breaking Biology Technology:BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 2Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 3Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 5Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 6Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 7Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 8Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 9DIATHERIX Laboratories Presents at Homeland Security Conference 2
...ped innovative process is making waves in the nano...ew companies in the process. A new company based i...dard Space Flight Center,s unique single-walled ca...ns to make high-quality, low-cost SWCNTs available...ology are vast and include medical, construction, ...
...an Coulter,Inc. (NYSE: BEC ), a leading developer...lify, automate, and innovate complex biomedical te...Coulter,s president and chief,executive officer, w...nference on Tuesday, September 11, 2007, at 11:00 ...n/prnh/20031202/BECLOGO ) The live webcast of Bec...
...se of Business Today - VGNI Stock ... 4 Viragen,International, Inc. (OTC Bulletin Boar...Inc. (OTC Bulletin Board: VRAI), today announced t...its issued and outstanding common stock,will becom...ber 4, 2007. The reverse stock split was first an...
Other Biology Technology:NASA technology forms the basis for a new nanotechnology company 2Beckman Coulter to Present at the Bear Stearns Healthcare Conference 2Viragen International to Reverse Split Its Common Stock 2Viragen International to Reverse Split Its Common Stock 3
(Date:11/4/2009)...FirstCall/ -- Aware, Inc. (Nasdaq: AWRE ), a lead...s software, today reported financial results for i..., Michael Tzannes, Aware,s Chairman and Chief Exec...an agreement to sell our DSL and home networking p...r company being spun out of Infineon. This transa...
(Date:11/4/2009)...tCall/ -- BIO-key International, Inc. (OTC Bulleti... identification software is showcasing donor and p...nce being held at the New Orleans Convention Cente...nds-on product demonstrations of its state-of-the-... at 5 PM on Monday, October 26, Peter Lux, manager...
(Date:11/4/2009).../ -- GenVault Corporation (Carlsbad, CA) today ann... its Board of Directors. Dr. Brody, the Irwin Jac...n acclaimed physician-scientist and university lea...dy served as president of The Johns Hopkins Univer...ngineering and the Institute of Medicine, and is r...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2009 Financial Results 2Aware, Inc. Reports Third Quarter 2009 Financial Results 3Aware, Inc. Reports Third Quarter 2009 Financial Results 4Aware, Inc. Reports Third Quarter 2009 Financial Results 5Aware, Inc. Reports Third Quarter 2009 Financial Results 6Aware, Inc. Reports Third Quarter 2009 Financial Results 7BIO-key(R) International Exhibiting at AABB TXPO 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia 48374 1Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia 48374 2Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia 48374 3Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia 48374 4DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 48372 1DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 48372 2DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 48372 3The secret of a snakes slither 8777 1
...s vaginalis colonises the urogenital tract and cau...common non-viral STI. , University of Queensland P...cientists that worked on the project to sequence t...ments for both men and women. , Ms Dunne said t...enes and gene families of interest, particularly t...
...t study to date of genetic variation among chimpan...ed sorting of chimps into three populations—wester...nt genetic differences, two to three times greater...an populations. , In the April 2007 issue of the ...sity of Chicago, Harvard, the Broad Institute and ...
...C. von Borstel, cancer is a metaphorical example o...the first pregnant finch that landed on a deserted...ncer cell in the human body has to undergo many mu...lf as an invader of different organs in the body. ...ecies in different ecological niches, cancer is to...
Other Biology News:Scientists perform 'tricky' operation 2Gene study shows three distinct groups of chimpanzees 2Cancer that colonizes our bodies 2
...sents the state-of-the-art in permanent mounting m...n of immunohistochemical organic insoluble substra...Fuchsin, and any other organic solvent compatible ...n be used for histology and cytology applications ...
pLivSelect PCR Cloning Kit R from Bio S&T
...Express is the first fully automated proteomics wo...fer operations with complete data tracking. It aut...colony picking through final protein expression an...le of delivering a plate to any of its instruments...
OLIGO from Molecular Biology Insights
Biology Products: